Second European Clinical Site Uses CoreValve's Novel ReValving(TM) System to Non-Surgically Replace Diseased Aortic Heart Valve of 77-Year-Old Female Patient Who Was Not Eligible for Open-Heart Surgery.

IRVINE, Calif., & PARIS -- CoreValve

"The successful completion of CoreValve's feasibility trials at Siegburg Heart Center (Germany) has validated the desirability of initiating learning-curve cases at additional interventional cardiology centers. Rotterdam's prestigious Erasmus Thoraxcenter was a logical first candidate for our expanding clinical trial."

--Jacques Seguin, MD, PhD, Chairman, CEO and Founder, CoreValve

CoreValve (www.corevalve.com) announced today that standard follow-up testing, conducted several days after a percutaneous ReValving(TM) procedure was performed in a second European clinical site to replace a patient's defective aortic heart valve, showed perfect functioning and anchoring of the new biological heart valve. Because of ReValving, the 77-year-old high-surgical-risk female patient was able to avoid open-heart surgery. The successful procedure was performed by Professor Patrick W. Serruys, a globally recognized interventional cardiologist who has been a leading investigator in clinical trials of numerous cutting-edge technologies, and Dr. Peter DeJaegere at Erasmus University Medical Center, Rotterdam, the Netherlands; they were assisted by Dr. Jean-Claude Laborde, an interventional cardiologist at Clinique Pasteur, Toulouse, France, who has had extensive clinical experience with the CoreValve Percutaneous ReValving System(TM).

"I was pleasantly surprised at the ease of use of the CoreValve Percutaneous ReValving System. Being able to perform this procedure in a cath lab is why ReValving has extraordinary possibilities for interventionally treating the thousands of patients who have defective aortic heart valves, but who are contraindicated for open-heart surgery," said Professor Serruys. "Given this patient's fragile pre-op condition, I am very impressed that her cardiac function is now significantly enhanced, as measured via post-procedure echocardiography."

CoreValve's system is used to replace an aortic heart valve via a percutaneous approach--on a beating heart. Excluding prep time, the second-generation CoreValve Percutaneous ReValving System used at Erasmus University Medical Center facilitated delivery and placement of a porcine pericardial-tissue bioprosthesis, via a 21-French-sized catheter, during a 10-minute procedure.

"This patient's pre-operative condition was substantially impaired due to significant aortic valve stenosis and a severely calcified aorta," said Dr. Jacques Seguin, founder, chairman and CEO of CoreValve. "Indeed, she was not considered a candidate for open-heart surgery by the surgeons at the University of Erasmus Medical Center because of her high-risk status and, in fact, this patient was out of options had it not been for CoreValve's non-surgical ReValving approach to treat her diseased aortic heart valve."

About CoreValve

Privately held CoreValve, with U.S. headquarters in Irvine, Calif., has developed a proprietary delivery system for percutaneous heart valve replacement, based on a novel catheter-and-self-expanding-frame approach on a beating heart, thus avoiding open-heart surgery. The CoreValve procedure--with the proprietary CoreValve Percutaneous ReValving System(TM)--can be performed in a cardiac "cath lab" just like angioplasty and stenting, resulting in less trauma to the patient and substantial cost-savings to the healthcare system. For more information about CoreValve, visit the Company's Web site at www.corevalve.com.

This news release contains certain "forward-looking" statements under the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of CoreValve, are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the protection of intellectual property, changes to governmental regulation of medical devices, the FDA's approval of new products, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the interventional cardiology industry and the economy and other factors.